Tiotropium Respimat inhaler and the risk of death in COPD.
暂无分享,去创建一个
G. Pledger | R. Dahl | A. Anzueto | P. Calverley | R. Wise | T. Devins | D. Dusser | B. Disse | D. Cotton | S. Kattenbeck | Elizabeth Joseph | Michael Koenen-Bergmann
[1] B. Plaud,et al. Etomidate and general anesthesia: the butterfly effect? , 2013, Anesthesia and analgesia.
[2] B. Celli,et al. Treadmill endurance during 2-year treatment with tiotropium in patients with COPD: a randomized trial. , 2013, Chest.
[3] R. Albert. "Lies, damned lies ..." and observational studies in comparative effectiveness research. , 2013, American journal of respiratory and critical care medicine.
[4] G. Pledger,et al. The Tiotropium Safety and Performance in Respimat® Trial (TIOSPIR®), a large scale, randomized, controlled, parallel-group trial-design and rationale , 2013, Respiratory Research.
[5] K. Verhamme,et al. Use of tiotropium Respimat Soft Mist Inhaler versus HandiHaler and mortality in patients with COPD , 2013, European Respiratory Journal.
[6] Hsien-Ho Lin,et al. Comparative safety of inhaled medications in patients with chronic obstructive pulmonary disease: systematic review and mixed treatment comparison meta-analysis of randomised controlled trials , 2012, Thorax.
[7] P. Enright,et al. Pro-arrhythmic and pro-ischaemic effects of inhaled anticholinergic medications , 2012, Thorax.
[8] Sonal Singh,et al. Risks associated with tiotropium in chronic obstructive pulmonary disease: overview of the evidence to date , 2012, Therapeutic advances in drug safety.
[9] S. Salpeter. Do Inhaled Anticholinergics Increase or Decrease the Risk of Major Cardiovascular Events? , 2009, Drugs.
[10] P. Poole,et al. Tiotropium versus placebo for chronic obstructive pulmonary disease. , 2012, The Cochrane database of systematic reviews.
[11] P. Enright,et al. Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials , 2011, BMJ : British Medical Journal.
[12] K. Rabe,et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. , 2011, The New England journal of medicine.
[13] P. Calverley,et al. Bias due to withdrawal in long‐term randomised trials in COPD: Evidence from the TORCH study , 2011, The clinical respiratory journal.
[14] E. Bateman,et al. A one-year trial of tiotropium Respimat plus usual therapy in COPD patients. , 2010, Respiratory medicine.
[15] T. Michele,et al. The safety of tiotropium--the FDA's conclusions. , 2010, The New England journal of medicine.
[16] M. Decramer,et al. Cardiovascular safety of tiotropium in patients with COPD. , 2010, Chest.
[17] M. Decramer,et al. Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. , 2009, American journal of respiratory and critical care medicine.
[18] J. Castro‐Rodriguez,et al. Tiotropium and risk for fatal and nonfatal cardiovascular events in patients with chronic obstructive pulmonary disease: systematic review with meta-analysis. , 2009, Respiratory medicine.
[19] Y. Oba. Risk of major adverse cardiovascular events with inhaled anticholinergics in patients with chronic obstructive pulmonary disease. , 2009, JAMA.
[20] J. V. van Noord,et al. The efficacy of tiotropium administered via Respimat Soft Mist Inhaler or HandiHaler in COPD patients. , 2009, Respiratory medicine.
[21] H. Covelli. Risk of major adverse cardiovascular events with inhaled anticholinergics in patients with chronic obstructive pulmonary disease. , 2009, JAMA.
[22] M. Decramer,et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. , 2008, The New England journal of medicine.
[23] Bartolome Celli,et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. , 2007, The New England journal of medicine.
[24] J. Bourbeau,et al. Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis , 2006, Thorax.